|
Cardiovascular Pharmacology
Citations 151-160 of 640 total displayed.
|
Past content
(since Jan 1999):
|
- Original Articles
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
- James Brian Byrd, Karine Touzin, Saba Sile, James V. Gainer, Chang Yu, John Nadeau, Albert Adam, and Nancy J. Brown
Hypertension 2008;51:141-147; published online before print as doi:10.1161/HYPERTENSIONAHA.107.096552
[Abstract]
[Full text]
- Scientific Contributions
Low Concentrations of Sphingosylphosphorylcholine Enhance Pulmonary Artery Vasoreactivity. The Role of Protein Kinase C and Ca2+ Entry
- Vladimir A. Snetkov, Gavin D. Thomas, Bonnie Teague, Richard M. Leach, Yasin Shaifta, Greg A. Knock, Philip I. Aaronson, and Jeremy P.T. Ward
Hypertension published December 24, 2007, doi:10.1161/HYPERTENSIONAHA.107.104802
[Abstract]
- Scientific Contributions
Ethnic and Genetic Determinants of Cardiovascular Response to the Selective  2-Adrenoceptor Agonist Dexmedetomidine
- Daniel Kurnik, Mordechai Muszkat, Gbenga G. Sofowora, Eitan A. Friedman, William D. Dupont, Mika Scheinin, Alastair J.J. Wood, and C. Michael Stein
Hypertension published December 10, 2007, doi:10.1161/HYPERTENSIONAHA.107.098939
[Abstract]
- Brief Reviews
Role of Renin-Angiotensin System Blockade in Atherosclerotic Renal Artery Stenosis and Renovascular Hypertension
- Daniel G. Hackam, J. David Spence, Amit X. Garg, and Stephen C. Textor
Hypertension 2007;50:998-1003; published online before print as doi:10.1161/HYPERTENSIONAHA.107.097345
[Full text]
- Editorial Commentaries
LA419, a Novel Nitric Oxide Donor, Prevents Cardiac Remodeling Via the Endothelial Nitric Oxide Synthase Pathway: NO Donors as a Means of Antiremodeling
- Ludovit Paulis and Fedor Simko
Hypertension 2007;50:1009-1011; published online before print as doi:10.1161/HYPERTENSIONAHA.107.100032
[Full text]
- Original Articles
LA419, a Novel Nitric Oxide Donor, Prevents Pathological Cardiac Remodeling in Pressure-Overloaded Rats Via Endothelial Nitric Oxide Synthase Pathway Regulation
- Gema Ruiz-Hurtado, María Fernández-Velasco, Marisabel Mourelle, and Carmen Delgado
Hypertension 2007;50:1049-1056; published online before print as doi:10.1161/HYPERTENSIONAHA.107.093666
[Abstract]
[Full text]
- Original Articles
Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin II–Salt Hypertension
- Ahmed A. Elmarakby, Jeffrey E. Quigley, Jeffrey J. Olearczyk, Aarthi Sridhar, Anthony K. Cook, Edward W. Inscho, David M. Pollock, and John D. Imig
Hypertension 2007;50:1069-1076; published online before print as doi:10.1161/HYPERTENSIONAHA.107.098806
[Abstract]
[Full text]
- Editorial Commentary
Blood Pressure Targets After High-Risk Myocardial Infarction. Is It Time to Update the Guidelines?
- Scott J. Denardo, R. David Anderson, and Carl J. Pepine
Hypertension published November 26, 2007, doi:10.1161/HYPERTENSIONAHA.107.099291
[Abstract]
- Scientific Contributions
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
- James Brian Byrd, Karine Touzin, Saba Sile, James V. Gainer, Chang Yu, John Nadeau, Albert Adam, and Nancy J. Brown
Hypertension published November 19, 2007, doi:10.1161/HYPERTENSIONAHA.107.096552
[Abstract]
- Editorials
Maintaining Equilibrium by Selective Targeting of Cyclooxygenase Pathways: Promising Offensives Against Vascular Injury
- Ruba S. Deeb, Rita K. Upmacis, Brian D. Lamon, Steven S. Gross, and David P. Hajjar
Hypertension published November 12, 2007, doi:10.1161/HYPERTENSIONAHA.107.092866
[Abstract]
|
|
